Drug and Therapeutics Bulletin 1998;36:65-68; doi:10.1136/dtb.1998.36965
Copyright © 1998 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Montelukast and {blacktriangledown}zafirlukast in asthma

Relevant BNF section: 3.3

{blacktriangledown}Montelukast (Singulair - Merck Sharp & Dohme) and {blacktriangledown}zafirlukast (Accolate - Zeneca) are two of a new class of drugs for the treatment of asthma that have recently been marketed in the UK - the leukotriene receptor antagonists. Montelukast is licensed as add-on therapy in adults and children (6 years and over) with mild to moderate persistent asthma which is inadequately controlled by inhaled corticosteroids and 'as needed' short-acting ß-agonists. It is also licensed for the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction. Zafirlukast has recently been licensed in the UK "for the treatment of asthma" in adults and children (over 12 years of age). In this article, we assess the place of these two new drugs in the treatment of asthma.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1998 BMJ Publishing Group Ltd.